{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335059","form_type":"8-K","ticker":"TKNO","cik":"0001850902","company_name":"Alpha Teknova, Inc.","filed_at":"2026-08-05T20:06:41+00:00","discovered_at":"2026-08-05T20:08:00.245896+00:00","generated_at":"2026-08-05T20:09:32.986944+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Teknova Q2 revenue $12.2M (+18% YoY); raises FY 2026 guidance to $45-47M","bullets":["Q2 2026 revenue $12.2M, up 18% from $10.3M in Q2 2025; net loss narrowed to $3.2M ($0.06 loss per share).","Lab Essentials revenue $9.2M (+18% YoY); Clinical Solutions $2.4M (+18% YoY).","Gross margin improved to 40.1% from 38.7%; Free Cash Outflow reduced to $0.6M from $2.3M.","FY 2026 revenue guidance raised to $45-47M; Free Cash Outflow expected <$8M.","Launched AI-powered Build-Tek custom order configurator for faster preclinical-to-clinical manufacturing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335059","json":"https://secwatch.observer/filing/0001193125-26-335059.json","markdown":"https://secwatch.observer/filing/0001193125-26-335059.md","text":"https://secwatch.observer/filing/0001193125-26-335059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000119312526335059/0001193125-26-335059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000119312526335059/tkno-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:09:32.986944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}